跳至主導覽 跳至搜尋 跳過主要內容

Association of sodium–glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan

  • Tzu Yi Lin
  • , Eugene Yu Chuan Kang*
  • , Shih Chieh Shao
  • , Edward Chia Cheng Lai
  • , Nan Kai Wang
  • , Sunir J. Garg
  • , Kuan Jen Chen
  • , Je Ho Kang
  • , Wei Chi Wu
  • , Chi Chun Lai
  • , Yih Shiou Hwang*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Cheng Kung University
  • Columbia University
  • Thomas Jefferson University
  • Yang Ming Hospital
  • Taipei City Hospital
  • Xiamen Chang Gung Hospital

研究成果: 期刊稿件 › 文章 › 同儕審查

3 引文 斯高帕斯(Scopus)

摘要

Aims: Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are proposed to alleviate the development of inflammatory eye diseases. However, the association between SGLT2i and retinal vascular occlusion remains unclear. Therefore, this study aims to explore the effects of SGLT2i on the incidence of retinal vascular occlusion. Materials and Methods: This retrospective cohort study analysed electronic medical records data from the largest multi-institutional database in Taiwan. Individuals who initiated SGLT2is and dipeptidyl peptidase 4 inhibitors (DPP4is) between 2016 and 2019 were included in our analysis. To conduct a homogenous comparison, inverse probability of treatment weighting with propensity scoring was employed. The primary outcome was retinal vascular occlusion, and the secondary outcomes were retinal vascular occlusion-related complications (macular oedema, vitreous haemorrhage, and tractional retinal detachment) and conditions requiring vitreoretinal intervention (intravitreal injection, retinal laser therapy, and vitrectomy). Results: In total, 12,074 SGLT2i users and 39,318 DPP4i users were included. The incidence rate of retinal vascular occlusion in the SGLT2i and DPP4i groups was 1.2 (95% confidence interval [CI], 0.9–1.4) and 1.6 (95% CI, 1.3–1.8) events per 1000 person-years, respectively, which yielded a subdistribution hazard ratio (SHR) of 0.74 (95% CI, 0.55–0.99). Similar risk reductions were observed in the retinal vascular occlusion-related complications (SHR, 0.76; 95% CI, 0.69–0.84) and conditions requiring vitreoretinal intervention (SHR, 0.84; 95% CI, 0.77–0.94). Conclusions: In this multi-institutional study in Taiwan, SGLT2i use was associated with a reduced risk of retinal vascular occlusion. Further prospective studies are required to ascertain this association.

原文英語
文章編號e3773
頁(從 - 到)e3773
期刊Diabetes/Metabolism Research and Reviews
卷40
發行號2
DOIs
出版品狀態已出版 - 02 2024

文獻附註

© 2024 John Wiley & Sons Ltd.

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Association of sodium–glucose cotransporter-2 inhibitors and the risk of retinal vascular occlusion: A real-world retrospective cohort study in Taiwan」主題。共同形成了獨特的指紋。

引用此